Efficacy and quality-of-life improvements with fremanezumab treatment in patients with difficult-to-treat migraine with associated neurological dysfunction.
Christian LamplAlan M RapoportJoshua M CohenSteve BarashVerena Ramirez CamposMichael J SeminerioXiaoping NingStephen D SilbersteinPublished in: European journal of neurology (2022)
Fremanezumab reduced days with neurological symptoms, effectively prevented migraine, and improved quality of life in patients with migraine with associated neurological dysfunction, including those with previous inadequate response to two to four migraine preventive medication classes.